Edimer Secures $18M Series B Financing Led by New Enterprise Associates

Edimer Pharmaceuticals is a start-up that develops therapeutics for treatment of X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED), a rare genetic disease. The company has its scientific roots in Switzerland. In 2008 Christophe Maier launched Edimer Biotech to continue the pioneering development of EDI200, an orphan drug product for XLHED that was underway at another Swiss start-up which was acquired by a bigger company. Edimer Biotech went through the coaching process of the Innovation Promotion Agency CTI and received the CTI Start-up Label in 2009. In the same year Edimer Pharmaceuticals was established with investment from Third Rock Ventures and VI Partners and opened its office in the Boston Area.

Edimer Pharmaceuticals announced it has secured $18 million in Series B financing. The lead investor was New Enterprise Associates (NEA), with additional new investor Sanofi-Genzyme BioVentures, and previous investors Third Rock Ventures and VI Partners.

Edimer plans to use the proceeds from this financing to advance the later stage clinical development of EDI200, the company’s novel, proprietary, recombinant protein being developed for the treatment of XLHED. If fully developed and approved, EDI200 will be the first drug to treat the symptoms of this ultra-rare genetic disorder. In addition, Edimer will explore additional opportunities to leverage its expertise and leadership position in ecotdysplasin biology. Edimer is currently looking for women that know or suspect that they are carriers of XLHED who are pregnant or thinking of expanding their families. Male infants born with XLHED may be eligible to participate in the Phase 2 clinical study.